Education
About Us
Working with TipRanks
Follow Us
Serina Therapeutics (SER)
:SER
SER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $10.28
Previous CloseN/A
Volume4.86K
Average Volume (3M)29.27K
Market Cap
$54.92M
Enterprise Value$51.32M
Total Cash (Recent Filing)$4.27M
Total Debt (Recent Filing)$227.00K
Price to Earnings (P/E)―
Beta-0.73
Next Earnings
Aug 08, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding9,967,381
10 Day Avg. Volume40,093
30 Day Avg. Volume29,271
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue789.53
Enterprise Value/Gross Profit-1.07K
Enterprise Value/Ebitda-92.80
Forecast
1Y Price Target
$15.00Price Target Upside172.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Drug InnovationSER-252 could represent a best-in-class solution for deployment of apomorphine in advanced PD patients.
Market OpportunityMarket metrics appear extremely attractive, with PD afflicting more than 1 million patients in the U.S. alone.
Regulatory PathwayThe discussion highlighted the company's clear vision of SER-252's path for regulatory approval, with a potential for 505(b)2 and associated reductions in timelines and costs, and their confidence they can reach the clinical benchmarks required to be approved.
Bears Say
Market Challenges63% of patients treated with competing product ONAPGO experience infusion site reactions, highlighting potential challenges in the market.
Treatment ComplianceCurrent formulations of apomorphine (APOKIN and ONAPGO, both marketed by Supernus Pharmaceuticals) have severe adverse events, which can hinder treatment compliance.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $3.81 and its highest was $10.28 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $54.92M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Aug 08, 2025 which is 3 days ago.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on May 08, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.62 by $0.13.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 9,967,381 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.62. Following the earnings report the stock price went up 1.101%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in SER
Serina Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (172.23% Upside)
$15.00 (172.23% Upside)
Insider Transactions
Sold Shares
Worth $235.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.81%
12-Months-Change
Fundamentals
Return on Equity
45.59%
Trailing 12-Months
Asset Growth
-38.00%
Trailing 12-Months
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
SER Stock 12 Month Forecast
Average Price Target
$15.00
▲(172.23% Upside)
Technical Analysis
PDS Biotechnology
―
Verrica Pharmaceuticals
―
Sutro Biopharma
―
Kronos Bio
―
Gain Therapeutics
―
Ownership Overview
64.66% Insiders
0.89% Mutual Funds
<0.01% Other Institutional Investors
32.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---